Exosome Biochemical Marker & Composition Analysis

Q: What is protein-to-particle ratio, and why does it matter?

Protein-to-particle ratio (pg protein per 109 particles) is a purity metric that normalizes protein content against vesicle count. A high ratio may indicate protein aggregate contamination or excessive cargo loading. A low ratio may suggest membrane damage or incomplete purification. This metric is valuable for batch-to-batch consistency monitoring and CQA trending. Note that acceptable ratio ranges vary significantly depending on bacterial strain, culture conditions, and purification protocol; we establish batch-specific baselines for each client project.

Inquiry

OverviewServicesSamplesAdvantagesApplicationsCase StudyFAQs

Overview

At Creative BioMart Microbe, we provide comprehensive biochemical marker and composition analysis services purpose-built for microbial extracellular vesicles (mEVs), including bacterial outer membrane vesicles (OMVs), cytoplasmic membrane vesicles (CMVs) from Gram-positive bacteria, fungal EVs, and vesicles from phage-infected bacterial cultures. Our platform integrates targeted quantification of outer membrane proteins (OMPs), lipopolysaccharide/lipoteichoic acid (LPS/LTA), total protein content, and total lipid content into a single, standardized analytical workflow that delivers quantitative, reproducible composition data aligned with industry standards for extracellular vesicle characterization.

Unlike generic proteomics or lipidomics CROs that apply mammalian protocols to microbial samples, we have optimized every extraction, quantification, and detection parameter for the unique biochemical architecture of mEVs. From purified vesicle suspension to publication-ready report, clients receive validated marker abundance, composition ratios, and purity metrics that support critical quality attribute (CQA) documentation, lot-release testing, and regulatory submissions for OMV-based vaccines, probiotic-derived therapeutics, and cosmetic actives. Contact us to discuss your specific marker panel and analytical requirements.

Scientific schematic of integrated biochemical marker and composition analysis platform for microbial extracellular vesicles, showing OMP quantification, LPS-LTA analysis, total protein profiling, and total lipid profiling modules converging into a unified composition report.
Figure 1. Schematic overview of the integrated biochemical marker and composition analysis platform for microbial extracellular vesicles, spanning OMP profiling, LPS/LTA quantification, total protein analysis, total lipid analysis, and cross-validated composition reporting.

Services

Commercial end-to-end service workflow diagram for biochemical marker and composition analysis showing seven stages from sample inquiry through sample receipt, vesicle lysis, OMP extraction, LPS-LTA quantification, protein-lipid profiling, data integration, and final report delivery.

Inquiry

Service Details

Isometric laboratory automation scene showing robotic liquid handling arms processing 96-well microplates for outer membrane protein ELISA quantification with fluorescent readout and automated sample tracking.

Outer Membrane Protein (OMP) Quantification & Profiling

We quantify outer membrane protein abundance using enzyme-linked immunosorbent assay (ELISA) and targeted proteomics workflows optimized for mEV samples. Our OMP panel includes BamA, OmpA, OmpC, OmpF, and species-specific markers validated for E. coli, Pseudomonas aeruginosa, and Salmonella OMVs. For Gram-positive CMVs, we profile cell-wall anchored proteins and surface-associated virulence factors. Deliverables include absolute protein concentration (ng/mL), protein-to-particle ratio, and relative abundance across marker subtypes. Optional western blot confirmation is available for regulatory submissions.

Molecular close-up illustration showing lipopolysaccharide (LPS) and lipoteichoic acid (LTA) molecular structures on microbial vesicle membranes with antibody binding sites highlighted in teal and orange.

Lipopolysaccharide/Lipoteichoic Acid (LPS/LTA) Quantification

We measure LPS (Gram-negative) and LTA (Gram-positive) content using Limulus amebocyte lysate (LAL) chromogenic endpoint assays and competitive ELISA as primary quantification methods. HPLC-based profiling with UV or mass spectrometry detection is applied for LPS molecular weight distribution and purity assessment. LPS quantification is critical for OMV vaccine CQA documentation, as endotoxin activity directly correlates with immunogenicity and safety profiles. LTA quantification supports CMV-based probiotic product characterization. Results are expressed in endotoxin units (EU/mL), weight concentration (µg/mL), and LPS/LTA-to-total-protein ratios.

3D product rendering of analytical instruments including a nanoDrop spectrophotometer, BCA assay workstation with cuvettes, and LC-MS system for label-free proteomic profiling of microbial vesicles.

Total Protein Quantification & Proteomic Profiling

We determine total protein content using bicinchoninic acid (BCA) and Bradford assays calibrated with bovine serum albumin (BSA) standards. For in-depth protein composition analysis, we offer label-free quantitative proteomics by liquid chromatography-tandem mass spectrometry (LC-MS/MS), identifying and quantifying hundreds to thousands of vesicle-associated proteins. This service enables cargo profiling, host cell protein (HCP) detection, and functional pathway annotation for OMVs, CMVs, and fungal EVs. Deliverables include protein concentration, spectral counts, peptide identification reports, and Gene Ontology (GO) enrichment analysis.

Biological cross-section illustration showing microbial vesicle membrane bilayer structure with phospholipids, cardiolipins, and lipid-A molecules embedded in the membrane, depicted in textbook scientific illustration style.

Total Lipid Quantification & Lipidomic Profiling

We quantify total lipid content using the Bligh-Dyer extraction method followed by phosphate determination or LC-MS-based lipidomics. Our lipidomic profiling identifies phospholipid classes (phosphatidylethanolamine, phosphatidylglycerol, cardiolipin), fatty acid composition, and lipid-A variants specific to Gram-negative OMVs. For fungal EVs, we profile ergosterol, sphingolipids, and glycerophospholipids. This analysis is essential for understanding membrane stability, immunogenicity, and formulation behavior. Results include total lipid concentration (µg/mL), lipid-to-protein ratio, and relative abundance of lipid classes.

Abstract data visualization showing flowing data streams converging into an integrated biochemical composition dashboard with heatmaps, bar charts, and cross-validation metrics for microbial vesicle marker profiling.

Integrated Biochemical Composition Report & Cross-Validation

All individual marker analyses are consolidated into a unified composition report with cross-validated metrics. OMP abundance is correlated with total protein content; LPS/LTA values are normalized per particle (using NTA-derived concentration); lipid class distributions are mapped against membrane biogenesis pathways. Statistical analysis includes coefficient of variation (CV) across technical replicates, confidence intervals for mean concentrations, and outlier detection algorithms. Reports are delivered in PDF and raw data formats (Excel, CSV, mzML for MS data), supporting direct integration into CMC documentation and regulatory filings.

Service Specifications & QC Standards

Instrumentation & Capability

OMP ELISA: Automated 96-well plate reader (SpectraMax iD3 or equivalent), absorbance at 450 nm.
OMP Targeted Proteomics: nanoLC-MS/MS (Orbitrap Exploris 480 or equivalent) with data-independent acquisition (DIA).
LPS/LTA LAL: FDA-licensed kinetic chromogenic LAL assay (Lonza PyroGene or equivalent), sensitivity 0.01–100 EU/mL.
LPS/LTA ELISA: Custom monoclonal antibody panels for E. coli O111:B4, P. aeruginosa serotype-specific LPS.
Total Protein: BCA (Thermo Pierce) and Bradford (Bio-Rad) microplate assays, BSA standard curve 0.2–2.0 mg/mL.
Label-Free Proteomics: nanoLC-MS/MS with DDA or DIA, MaxQuant or DIA-NN quantification.
Total Lipid: Bligh-Dyer extraction, LC-MS (Q Exactive Focus or equivalent) with HILIC separation.
Sample input per assay: 10–100 µg total protein equivalent (vesicle lysate).

Typical Data Range

OMP ELISA detection range: 0.1–50 ng/mL per marker.
LPS LAL detection range: 0.01–100 EU/mL; cross-reactivity <1% with LTA.
Total protein BCA assay range: 5–2000 µg/mL.
Label-free proteomics: 200–2000+ protein identifications per sample.
Total lipid quantification range: 1–500 µg/mL.
Lipidomic classes: 50–200 lipid species identified per sample.

Turnaround Time

Project Type	Timeline
OMP ELISA only	5–7 business days
LPS/LTA LAL only	3–5 business days
Total protein BCA/Bradford only	2–3 business days
Label-free proteomics	14–21 business days
Lipidomic profiling	14–21 business days
Standard package (OMP + LPS + Protein + Lipid)	21–28 business days
Expedited analysis	+50% fee, 50% time reduction

Timeline may vary based on sample type, volume, and assay customization requirements.

Deliverables

OMP ELISA: Standard curve, sample concentrations, protein-to-particle ratio, intra-assay CV.
LPS/LTA: Endotoxin concentration (EU/mL), weight equivalent (µg/mL), lot comparison table.
Total Protein: BSA standard curve, sample concentrations, total protein yield per batch.
Proteomics: Protein identification list, quantitative abundance table, GO enrichment, pathway analysis.
Lipidomics: Lipid class abundance, fatty acid profile, lipid-A variant identification (for OMVs).
Integrated report: Cross-validated composition summary, statistical analysis, QC flags.
Certificate of Analysis (CoA) per batch.

Quality Control

Standard curve R² ≥ 0.99 for all colorimetric and ELISA assays.
Positive controls: Commercial LPS (O111:B4), BSA standards, validated OMP peptide standards.
Negative controls: Reagent blanks, buffer-only wells, vesicle-depleted supernatant.
Intra-assay CV ≤ 10%; inter-assay CV ≤ 15%.
MS-based proteomics: FDR ≤ 1% at peptide and protein level; minimum 2 unique peptides per protein.
Lipidomics: Internal standard calibration (deuterated lipid classes); matrix effect evaluation.
Compliance checklist for minimal characterization requirements aligned with industry guidelines for extracellular vesicle studies.
Optional GxP-aligned assay validation and CQA trending analysis for lot-release documentation.

Sample Requirements

Required Information	Optional Information	Not Accepted
Sample type (OMVs, CMVs, fungal EVs, phage vesicles) Purified vesicle suspension or crude lysate Approximate total protein concentration (if known) Sample volume (minimum 100 µL for standard panel) Buffer composition and pH Species/strain identification Storage conditions and shipping temperature	Prior purification method and yield data Target application (research, CMC, regulatory) Specific marker panel requests (non-standard OMPs) Reference batch for comparison studies Regulatory documentation requirements (CoA format)	Samples in organic solvents or detergents (>0.1% SDS) Samples with visible precipitation or aggregation Samples without proper cold-chain documentation Intact bacterial/fungal cell cultures (must be clarified) Contaminated or mixed samples Samples shipped at room temperature

Recommended Sample Quantity by Assay:

Assay	Minimum Volume	Recommended Volume
OMP ELISA	50 µL	100 µL
LPS/LTA LAL	50 µL	100 µL
Total Protein BCA	20 µL	50 µL
Label-free Proteomics	100 µL	200 µL
Lipidomic Profiling	100 µL	200 µL
Standard package (all assays)	200 µL	500 µL

Storage & Shipping: Ship purified vesicle suspensions on dry ice (–80°C) or wet ice (4°C) with cold-chain documentation. Avoid repeated freeze-thaw cycles. Recommended buffer: sterile PBS or Tris-buffered saline. For proteomics and lipidomics, ship in low-detergent buffers (≤0.05% Triton X-100 or equivalent).

Inquiry

Our Advantages

Microbial EV-Specific Marker Panels: Our OMP, LPS, and LTA assays are calibrated against microbial vesicle matrices, not mammalian exosome standards. We account for lipid-A variants, species-specific OMP epitopes, and cell-wall debris interference that generic CROs overlook.
Integrated Multi-Modal Composition Platform: Protein, lipid, and polysaccharide analyses are performed under harmonized sample preparation and data normalization standards. Cross-validation between colorimetric, immunological, and mass spectrometry methods eliminates method-specific bias.
Regulatory-Ready CQA Documentation: Our standard deliverables include CoA, standard curve documentation, intra/inter-assay precision data, and method validation summaries in formats compatible with IND-enabling CMC packages and lot-release specifications.
Flexible Marker Panel Customization: Beyond standard BamA, OmpA, and O111:B4 LPS panels, we develop custom ELISA and targeted MS assays for client-specific markers, enabling species-specific OMV characterization and competitor product benchmarking.
Quantitative Cross-Validation: Every composition report correlates marker concentrations with particle counts (from NTA), enabling per-particle normalization (e.g., pg LPS per 10⁹ particles) that is essential for dose-standardized therapeutic and vaccine applications.

Applications

Vaccine adjuvant OMV quality control application showing central OMV particle surrounded by OMP, LPS, protein, and lipid composition modules with lot-release specification checkmarks.

OMV Vaccine CQA & Lot-Release QC

LPS endotoxin quantification and OMP profiling ensure OMV vaccine lots meet immunogenicity and safety specifications for regulatory submission.

Therapeutic mEV nanocarrier formulation application showing left-to-right workflow from laboratory analysis instruments through vesicle membrane composition to therapeutic delivery outcome.

Therapeutic mEV Nanocarrier Formulation

Lipid and protein composition data predict membrane stability, drug loading capacity, and formulation shelf-life for mEV-based drug delivery systems.

Probiotic food-grade mEV composition claims application showing a gut lumen scene with Lactobacillus-derived membrane vesicles and surrounding functional modules for immune modulation and barrier enhancement.

Probiotic & Food-Grade mEV Composition Claims

Consistent protein and LTA profiling supports functional claims and safety documentation toward GRAS evaluation of probiotic-derived vesicle ingredients.

Cosmetic skin vesicle active ingredient validation application showing scale transition from macroscopic skin surface to microscopic vesicle fusion with skin cells and lipid bilayer interaction.

Cosmetic Skin Vesicle Active Ingredient Validation

Lipid composition and protein cargo profiling validate cosmetic mEV actives for dermal penetration and bioactivity claims.

Case Study

Case Study: Lipidomic and Proteomic Profiling of Xanthomonas citri Outer Membrane Vesicles

Xanthomonas citri pv. citri is a Gram-negative plant pathogen whose outer membrane vesicles (OMVs) play a role in host colonization and microbial community modulation. Researchers employed a multi-modal biochemical characterization strategy combining LC-MS lipidomics and LC-MS/MS proteomics to define the composition of X. citri OMVs and identify functional cargo linked to virulence and resource sharing.

Lipidomic analysis revealed enrichment in saturated cardiolipins within OMV membranes, distinguishing vesicle lipidomes from their parent cell membranes. Proteomic profiling identified outer membrane-associated TonB-dependent receptors, siderophore-binding proteins, and metal ion transporters. Direct biochemical assays confirmed the presence of siderophores within vesicle cargo via chrome azurol S (CAS) discoloration, while elemental analysis (TQ ICP-MS) quantified essential metals including iron, zinc, and manganese. These findings suggest OMVs function as virulence-associated cargo carriers facilitating nutrient acquisition during host colonization. Functional assays further confirmed esterase and protease activities, supporting a role in extracellular nutrient scavenging and host tissue degradation. This study demonstrates how integrated biochemical composition analysis can link mEV molecular content to biological function.

LC-MS lipidomic analysis of Xanthomonas citri OMVs and whole cells showing six lipid subclasses, comparative abundance profiles, and saturated cardiolipin enrichment versus unsaturated lipid depletion.
Figure 2. Lipidomic analysis of X. citri whole cells and OMVs. (Araujo, et al. 2025)

FAQs

Q: What is the difference between total protein and OMP quantification?

A: Total protein quantification measures all proteinaceous material in a vesicle sample (including cargo, membrane proteins, and contaminants) using BCA or Bradford assays. OMP quantification specifically targets outer membrane proteins (e.g., BamA, OmpA) using antibody-based ELISA or targeted proteomics. OMP data is essential for vesicle identity confirmation and purity assessment, while total protein measures overall yield.

Q: Why is LPS quantification important for OMV products?

A: Lipopolysaccharide is the primary immunostimulatory component of Gram-negative OMVs. For vaccine adjuvant applications, controlled LPS content ensures consistent immunogenicity without excessive reactogenicity. For therapeutic applications, low LPS levels are required to prevent pyrogenic responses. LPS quantification is therefore a critical quality attribute for regulatory compliance.

Q: Can you analyze fungal EV lipid composition?

A: Yes. Our lipidomic platform is optimized for fungal EVs, profiling ergosterol, sphingolipids, glycerophospholipids, and sterol esters. Fungal membranes differ significantly from bacterial membranes in lipid composition, and our extraction and LC-MS methods account for these differences, including higher sterol content and distinct phospholipid headgroup distributions.

Q: How much sample do I need for a full composition panel?

A: The standard composition panel (OMP ELISA + LPS LAL + total protein + total lipid) requires a minimum of 200 µL of purified vesicle suspension at ≥0.5 mg/mL total protein equivalent. For proteomic and lipidomic profiling, we recommend 500 µL to allow for technical replicates and method optimization. Contact us for sample-specific recommendations.

Q: What is protein-to-particle ratio, and why does it matter?

A: Protein-to-particle ratio (pg protein per 10⁹ particles) is a purity metric that normalizes protein content against vesicle count. A high ratio may indicate protein aggregate contamination or excessive cargo loading. A low ratio may suggest membrane damage or incomplete purification. This metric is valuable for batch-to-batch consistency monitoring and CQA trending. Note that acceptable ratio ranges vary significantly depending on bacterial strain, culture conditions, and purification protocol; we establish batch-specific baselines for each client project.

Q: Can you develop custom ELISAs for non-standard OMP markers?

A: Yes. We offer custom antibody development and ELISA validation for species-specific OMPs, adhesins, or virulence factors not covered by our standard panel. Typical development timeline is 8–12 weeks, including peptide immunogen design, antibody production, and assay validation.

Q: How do you ensure lot-to-lot consistency in biochemical assays?

A: We implement rigorous QC standards including daily instrument calibration with certified reference materials, positive and negative controls in every assay plate, intra-assay CV targets ≤10%, and inter-assay CV targets ≤15%. For recurring production batches, we establish control charts tracking each CQA over time, flagging deviations beyond predefined acceptance criteria.

Q: Is your composition analysis compatible with GxP requirements?

A: Our standard service is research-grade (R&D) with validated methods and full QC documentation. GxP-aligned analysis (IQ/OQ/PQ instrument qualification, method validation per ICH Q2(R1), audit trails, and CoA signing) is available as a custom service with additional quality oversight and documentation. Contact us to discuss your regulatory pathway requirements.

References:

Araujo, G.G., et al. (2025). Functional cargo in membrane vesicles from a citrus pathogen. Environmental Microbiology Reports, 17(4), e70101.

Services

Inquiry